Skip to Content

Propel Approval History

FDA Approved: Yes (First approved August 15, 2011)
Brand name: Propel
Generic name: mometasone furoate
Dosage form: Implant
Company: Intersect ENT, Inc.
Treatment for: Sinusitis

Propel (mometasone furoate) is a corticosteroid implant offering localized, controlled drug delivery for chronic sinusitis patients.

Development History and FDA Approval Process for Propel

Aug 15, 2011Approval Intersect ENT Announces U.S. Food and Drug Administration Approval for Propel - First Drug Releasing Implant for Chronic Sinusitis Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.